Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA - Top-Institutions - MDSpire

Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA

  • By

  • Kun Wang

  • Feini Xu

  • Lingjie Zhu

  • Jiaying Wang

  • Haibo Li

  • Xianwen Cao

  • Xuhan Wang

  • Da Zong

  • Yuankun Liu

  • Junfei Shao

  • May 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber/Harvard Cancer Center
    Dana-Farber/Harvard Cancer Center

    Boston, Massachusetts

    Key Differentiators

    • Neuro-Oncology
    • Cancer Epigenomics

  • #2

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Neuro-Oncology
    • Cancer Genetics

  • #3

    University Medical Center Hamburg-Eppendorf
    University Medical Center Hamburg-Eppendorf

    Hamburg, Germany

    Key Differentiators

    • Oncology

  • #4

    Public Health England
    Public Health England

    Salisbury, United Kingdom

    Key Differentiators

    • Public Health
    • Oncology

  • #5

    European Organisation for Research and Treatment of Cancer
    European Organisation for Research and Treatment of Cancer

    Brussels, Belgium

    Key Differentiators

    • Oncology

Original Source(s)

Integrating multiomics to elucidate the role of chromatin remodeling in glioma and the antitumor mechanisms and therapeutic potential of targeting LMNA

  • by Kun Wang, Feini Xu, Lingjie Zhu, Jiaying Wang, Haibo Li, Xianwen Cao, Xuhan Wang, Da Zong, Yuankun Liu, Junfei Shao

  • May 8, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report